NCT04955743 2025-11-24Pembrolizumab and Lenvatinib in Patients With Brain Metastases From Melanoma or Renal Cell CarcinomaYale UniversityPhase 2 Terminated18 enrolled
NCT05263492 2025-10-02Study of Lenvatinib w/ Pembro in Black Participants w/Mismatch Repair-Prof Recurrent Endometrial CancerVirginia Commonwealth UniversityPhase 2 Terminated4 enrolled 8 charts
NCT04729348 2025-07-25Pembrolizumab And Lenvatinib In Leptomeningeal MetastasesMassachusetts General HospitalPhase 2 Terminated10 enrolled
NCT03630120 2021-07-14Adaptive Tyrosine Kinase Inhibitor (TKI) Therapy In Patients With Thyroid CancerH. Lee Moffitt Cancer Center and Research InstitutePhase 2 Terminated6 enrolled 9 charts
NCT03433703 2019-12-06Trial to Evaluate Safety and Efficacy of Treatment of Physician Choice (TPC) Following First-Line Treatment of Lenvatinib in Subjects With Unresectable Hepatocellular Carcinoma (uHCC)Eisai Inc.Phase 2 Terminated8 enrolled 8 charts
NCT02657369 2019-10-15A Phase 2 Trial of Lenvatinib for the Treatment of Anaplastic Thyroid Cancer (ATC)Eisai Inc.Phase 2 Terminated34 enrolled 13 charts